期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 19, 期 1, 页码 3-25出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2005.01.032
关键词
allogenic bone marrow transplant; B cell-chronic lymphocytic leukemia (CLL); blistering skin disease; chronic inflammatory demyelinating polyneuropathy; Guillian-Barre syndrome; immunodeficiency; ITP; IVIG; Kawasaki disease; pediatric HIV; toxic epidermal ecrolysis
类别
Intravenous immunoglobulin G (IVIG) has become increasingly important both as replacement therapy in primary and acquired humoral immunodeficiency and as an immunomodulatory therapy in autoimmune disease and transplantation. Multiple potential mechanisms for the effects of IVIG have now been recognized but the contribution of each mechanism in different diseases is uncertain. IVIG is generally well tolerated but serious side effects can occur and need to be addressed. IVIG has Food and Drug Administration (FDA) approval for a half dozen indications but these account for only about half the use of IVIG. This chapter reviews the development of IVIG for primary immunodeficiency, the evidence for efficacy of IVIG in autoimmune and inflammatory conditions, the risks associated with administration of IVIG, and steps that can be taken to minimize adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据